Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Pre-clinical testing for FSHD CRISPR-inhibition therapy
Principle Investigator: Associate Professor Peter Jones Research Institution: University of Nevada CRISPR technology provides an avenue for targeting and correcting virtually any sequence in the human genome, with long-term or…
Read MoreFacio Therapies
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…
Read MoreDevelopment of next-generation AAV vectors for effective CRISPR inhibition of FSHD
Investigator: Charis L. Himeda, PhD, Research Assistant Professor, University of Nevada, Reno School of Medicine, Reno NV USA CRISPR technology provides an avenue for specifically targeting and manipulating virtually any…
Read MoreIdentify Biomarkers for FSHD Using Omics Approaches
Investigator: Yi-Wen Chen, Ph.D. (Children’s Research Institute in Silver Spring, Maryland) Biomarkers are biological changes that can be used as indicators of physiological and disease states. Biomarkers can be valuable…
Read MoreStryka-001 treatment in the FSHD-like mouse model
Investigator: Dean Burkin, PhD, and Peter Jones, PhD (University of Nevada, Reno School of Medicine) This is a project to validate the efficacy of a potential drug therapy for FSHD…
Read MoreA Xenograft Model of FSHD for Testing Therapeutics
Investigator: Robert J Bloch PhD, Professor of Physiology at the University of Maryland Facioscapulohumeral muscular dystrophy (FSHD) affects 1 in approximately 15,000 individuals worldwide. One of the obstacles in developing treatments…
Read More